BAF complex modulating compounds and methods of using the same

Patent metadata

Field	Value
Publication number	US-11267809-B2
Application number	US-201816635542-A
Country	US
Kind code	B2
Filing date	Sep 13, 2018
Priority date	Sep 14, 2017
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and provides effective compounds, pharmaceutical compositions, development strategies, and treatment protocols, and describes many of the ensuing benefits. A new family of BAF complex modulating compounds has been developed based on a new chemical scaffold including a 12-membered macrolactam core structures. Contacting target cells in vitro or in vivo with the compounds and compositions of this invention can selectively inhibit the activity of BAF complexes in such cells. Some of the BAF complex modulating compounds in this family are particularly effective agents for treating cancer in conjunction with a ATR inhibitor.

First claim

What is claimed is:

1. A method of modulating a BAF complex in a cell, the method comprising:
contacting a cell comprising a BAF complex with a BAF complex modulating compound to modulate the activity of a BAF complex in the cell, wherein the BAF complex modulating compound is a compound of formula (IA):

wherein:
R 1 is amine, substituted amine, alkylaminocarbonylamino, substituted alkylaminocarbonylamino, alkanoylamino, substituted alkanoylamino, arylaminocarbonylamino, substituted arylaminocarbonlamino, carbamate, substituted carbamate, aroylamino or substituted aroylamino;
R 2 is heteroaryl-aryl-alkyl, substituted heteroaryl-aryl-alkyl, aryl-heteroaryl-alkyl, substituted aryl-heteroaryl alkyl, alkanoyl or substituted alkanoyl; and
R 3 to R 6 are each independently H, alkyl or substituted alkyl;
or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cell is in vitro.

3. A method of treating cancer, the method comprising:
co-administering to a subject with cancer:
a therapeutically effective amount of a pharmaceutical composition comprising BAF complex modulating compound of formula (IA):

wherein:
R 1 is amine, substituted amine, alkylaminocarbonylamino, substituted alkylaminocarbonylamino, alkanoylamino, substituted alkanoylamino, arylaminocarbonylamino, substituted arylaminocarbonlamino, carbamate, substituted carbamate, aroylamino or substituted aroylamino;
R 2 is heteroaryl-aryl-alkyl, substituted heteroaryl-aryl-alkyl, aryl-heteroaryl-alkyl, substituted aryl-heteroaryl alkyl, alkanoyl or substituted alkanoyl; and
R 3 to R 6 are each independently H, alkyl or substituted alkyl;
or a pharmaceutically acceptable salt thereof; and
an ATR inhibitor;

to treat the subject for cancer.

4. The method of claim 3 , wherein the subject has cancer cells having a ARID1A-containing BAF complex and administration of the BAF complex modulating compound sensitizes the cancer cells to inhibition of ATR kinase.

5. The method of claim 4 , wherein the pharmaceutical composition and the ATR inhibitor act synergistically to kill cancer cells of the subject.

6. The method of claim 5 , wherein the synergistic action provides a reduction in the effective dose of the ATR inhibitor to an amount below a threshold of toxicity.

7. The method of claim 3 , wherein the subject has cancer cells harboring a BAF complex mutation.

8. A method of treating a BRCA1 cancer, the method comprising:
administering to a subject with a BRCA1 cancer a therapeutically effective amount of a pharmaceutical composition comprising BAF complex modulating compound of formula (IA):

wherein:
R 1 is amine, substituted amine, alkylaminocarbonylamino, substituted alkylaminocarbonylamino, alkanoylamino, substituted alkanoylamino, arylaminocarbonylamino, substituted arylaminocarbonlamino, carbamate, substituted carbamate, aroylamino or substituted aroylamino;
R 2 is heteroaryl-aryl-alkyl, substituted heteroaryl-aryl-alkyl, aryl-heteroaryl-alkyl, substituted aryl-heteroaryl alkyl, alkanoyl or substituted alkanoyl; and
R 3 to R 6 are each independently H, alkyl or substituted alkyl;
or a pharmaceutically acceptable salt thereof;
to treat the BRCA1 cancer.

9. The method of claim 8 , wherein the cancer is Breast Cancer, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Colon Cancer, Ovarian Cancer, Liver Cancer, Melanoma, Renal Cancer, Central Nervous System Cancer or Leukemia Lymphoma.

Assignees

• Univ Leland Stanford Junior

Inventors

• Chory Emma J
• Crabtree Gerald R
• Dykhuizen Emily C

Classifications

• C07D273/02

  having two nitrogen atoms and only one oxygen atom · CPC title

• C07D413/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title

• C07D413/14 Primary

  containing three or more hetero rings · CPC title